Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Jan 11

PMID 25576598

Citations 4

Authors

Andrea De Luca

Maurizio Zazzi

Affiliations

Soon will be listed here.

Citing Articles

Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.

Miti S, Handema R, Mulenga L, Mwansa J, Abrams E, Frimpong C PLoS One. 2020; 15(8):e0236156.

PMID: 32804970 PMC: 7430722. DOI: 10.1371/journal.pone.0236156.

Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?.

OMalley G, Barnabee G, Mugwanya K Curr HIV/AIDS Rep. 2019; 16(2):141-150.

PMID: 30796608 PMC: 6469867. DOI: 10.1007/s11904-019-00437-6.

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B PLoS One. 2019; 14(1):e0209605.

PMID: 30650082 PMC: 6334938. DOI: 10.1371/journal.pone.0209605.

Antiretroviral resistance testing in HIV-positive people.

Aves T, Tambe J, Ac Siemieniuk R, Mbuagbaw L Cochrane Database Syst Rev. 2018; 11:CD006495.

PMID: 30411789 PMC: 6517236. DOI: 10.1002/14651858.CD006495.pub5.

References

Vercauteren J, Wensing A, van de Vijver D, Albert J, Balotta C, Hamouda O . Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009; 200(10):1503-8. DOI: 10.1086/644505. View

von Wyl V, Yerly S, Burgisser P, Klimkait T, Battegay M, Bernasconi E . Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis. 2009; 48(7):979-87. DOI: 10.1086/597352. View

Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A . Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther. 2006; 11(3):329-34. View

Pham Q, Wilson D, Law M, Kelleher A, Zhang L . Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS. 2014; 28(18):2751-62. DOI: 10.1097/QAD.0000000000000494. View

Cozzi-Lepri A, Phillips A, Martinez-Picado J, Monforte A, Katlama C, Hansen A . Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009; 200(5):687-97. DOI: 10.1086/604731. View

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I . Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207(8):1216-20. DOI: 10.1093/infdis/jit017. View

Hue S, Gifford R, Dunn D, Fernhill E, Pillay D . Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol. 2009; 83(6):2645-54. PMC: 2648277. DOI: 10.1128/JVI.01556-08. View

Pingen M, Sarrami-Forooshani R, Wensing A, van Ham P, Drewniak A, Boucher C . Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. Retrovirology. 2014; 11:113. PMC: 4272521. DOI: 10.1186/s12977-014-0113-9. View

Prosperi M, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I . Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 2011; 66(8):1886-96. DOI: 10.1093/jac/dkr171. View

10.

De Luca A, Hamers R, Schapiro J . Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. J Infect Dis. 2013; 207 Suppl 2:S63-9. DOI: 10.1093/infdis/jit109. View

11.

Cambiano V, Bertagnolio S, Jordan M, Lundgren J, Phillips A . Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis. 2013; 207 Suppl 2:S57-62. DOI: 10.1093/infdis/jit111. View

12.

Paton N, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A . Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014; 371(3):234-47. DOI: 10.1056/NEJMoa1311274. View

13.

Taverne B, Desclaux A, Delaporte E, Ndoye I, Coll Seck A, Barre-Sinoussi F . Universal health coverage and HIV in resource-constrained countries: a critical juncture for research and action. AIDS. 2013; 27(14):2173-5. DOI: 10.1097/QAD.0b013e3283611a0e. View

14.

Santoro M, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F . Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014; 58(8):1156-64. DOI: 10.1093/cid/ciu020. View

15.

Yang W, Kouyos R, Scherrer A, Boni J, Shah C, Yerly S . Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. J Infect Dis. 2015; 212(1):28-38. DOI: 10.1093/infdis/jiv012. View

16.

Brenner B, Roger M, Moisi D, Oliveira M, Hardy I, Turgel R . Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS. 2008; 22(18):2509-15. PMC: 2650396. DOI: 10.1097/QAD.0b013e3283121c90. View

17.

Yerly S, Junier T, Gayet-Ageron A, El Amari E, von Wyl V, Gunthard H . The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS. 2009; 23(11):1415-23. DOI: 10.1097/QAD.0b013e32832d40ad. View

18.

Phillips A, Cambiano V, Miners A, Revill P, Pillay D, Lundgren J . Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2015; 1(2):e85-93. PMC: 4822192. DOI: 10.1016/S2352-3018(14)70021-9. View